RECOVERY Collaborative Group 2023, ' Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 401, no. 10387, pp. 1499-1507 . https://doi.org/10.1016/S0140-6736(23)00510-X
Mumford, A D & Gibbison, B J J 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 Dimitriadis, G K 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 RECOVERY Collaborative Group & Dark, P 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet . https://doi.org/10.1016/S0140-6736(22)01109-6
Lancet (London, England) LANCET RECOVERY Collaborative Group 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) a randomised controlled, open-label, platform trial ', The Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Mumford, A D 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial ', Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Group, RECOVERY C & Dark, P 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. ', Lancet (London, England), vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5
RECOVERY Collaborative Group & Downey, D 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5 LANCET Mumford, A, Ramanan, A V & Gibbison, B J J & Welch, H F 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5, https://doi.org/10.1016/S0140-6736(21)00149-5 The Lancet RECOVERY Collaborative Group, Felton, T, Evans, D G, Murray, C, Buch, M & Dark, P 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5
The Lancet Child & Adolescent Health, 2, 404-414 Lancet Child & Adolescent Health, Vol. 2, No 6 (2018) pp. 404-414 Lancet Child & Adolescent Health, 2(6), 404-414. Elsevier The Lancet Child & Adolescent Health, 2(6), 404-414. Elsevier BV The Lancet Child and Adolescent Health, 2(6), 404-414. Elsevier BV The Lancet Child and Adolescent Health, 2(6), 404-414. ELSEVIER SCI LTD Martinón-Torres, F, Salas, A, Gómez Rial, J, Rivero-Calle, I, Palacios, A & van Furth, A M 2018, ' Life-threatening infections in children in Europe (the EUCLIDS Project): a prospective cohort study ', The Lancet Child and Adolescent Health, vol. 2, no. 6, pp. 404-414 . https://doi.org/10.1016/S2352-4642(18)30113-5 The Lancet Child & Adolescent Health, 2, 6, pp. 404-414 The Lancet Child and Adolescent Health
Europe PubMed Central Lancet (London, England) RECOVERY Collaborative Group & Downey, D 2022, ' Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10320, pp. 143-151 . https://doi.org/10.1016/S0140-6736(21)01825-0 Group, RECOVERY C & Dark, P 2022, ' Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 399, no. 10320, pp. 143-151 . https://doi.org/10.1016/S0140-6736(21)01825-0 Mumford, A D 2022, ' Aspirin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10320, pp. 143-151 . https://doi.org/10.1016/S0140-6736(21)01825-0